Cancer Pharmacology
An Illustrated Manual of Anticancer Drugs
Herausgeber: Emadi, Ashkan; Karp, Judith E
Cancer Pharmacology
An Illustrated Manual of Anticancer Drugs
Herausgeber: Emadi, Ashkan; Karp, Judith E
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
"We are living in an exciting time for cancer pharmacology. The fusion of multiple disciplines of basic and clinical science is creating effective, life-prolonging therapies for a growing number of malignancies. The progress is electrifying and the promise for patients is exhilarating!"--
Andere Kunden interessierten sich auch für
- Tumor Board Review136,99 €
- Johnny NguyenHandbook of Hematologic Malignancies100,99 €
- Handbook of Benign Hematology89,99 €
- Oncology Board Review, Third Edition109,99 €
- Handbook of Stem Cell Transplantation and Cellular Therapy Management79,99 €
- Hematology Board Review109,99 €
- Pharmacogenetics of Breast Cancer109,99 €
-
-
-
"We are living in an exciting time for cancer pharmacology. The fusion of multiple disciplines of basic and clinical science is creating effective, life-prolonging therapies for a growing number of malignancies. The progress is electrifying and the promise for patients is exhilarating!"--
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Springer Publishing Company
- 2nd edition
- Seitenzahl: 454
- Erscheinungstermin: 13. November 2023
- Englisch
- Abmessung: 244mm x 185mm x 38mm
- Gewicht: 816g
- ISBN-13: 9780826149329
- ISBN-10: 0826149324
- Artikelnr.: 69514514
- Verlag: Springer Publishing Company
- 2nd edition
- Seitenzahl: 454
- Erscheinungstermin: 13. November 2023
- Englisch
- Abmessung: 244mm x 185mm x 38mm
- Gewicht: 816g
- ISBN-13: 9780826149329
- ISBN-10: 0826149324
- Artikelnr.: 69514514
Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland.
List of Contributors Preface PART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENT Chapter 1. Drug Development in Oncology 101 by Edward A. Sausville
MD
PhD and Ashkan Emadi
MD
PhD Chapter 2. Pharmacogenomics by Molly Graveno
PharmD
BCOP Chapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy
MD
Richard F. Little
MD
and Joshua F. Zeidner
MD Chapter 4. Drug Development and Regulatory Considerations by Vicky Hsu
PhD
Matthew D. Thompson
PhD
MPH
Donna Przepiorka
MD
PhD
and Olanrewaju O. Okusanya
Pharm.D.
MS PART 2. CLASSICAL CYTOTOXIC AGENTS Chapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi
MD
PhD and Edward A. Sausville
MD
PhD Chapter 6. Pyrimidine- and Purine-based Antimetabolites
Hydroxyurea
Asparaginases by Ashkan Emadi
MD
PhD and Judith E. Karp
MD Chapter 7. Antifolate Antimetabolites by Justin Lawson
PharmD
BCOP Chapter 8. Antimitotics by Edward A. Sausville
MD
PhD and Ashkan Emadi
MD
PhD PART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYS Chapter 9. Drugs Targeting DNA Repair
Cell Cycle and Apoptosis by Mira A. Kohorst
MD and Scott H. Kaufmann
MD
PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca
MD and Lukasz P. Gondek
MD
PhD Chapter 11. Differentiating Agents and Microenvironment by Yuya Nagai
MD
PhD and Gabriel Ghiaur
MD
PhD PART 4. ORGAN-TARGETED APPROACHES Chapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu
MD and Ashkan Emadi
MD
PhD Chapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton
PhD and Katherine H. R. Tkaczuk
MD Chapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar
PhD
and Arif Hussain
MD Chapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples
PharmD
BCOP and Sagar Lonial
MD PART 5. IMMUNE-TARGETED STRATEGIES Chapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic
MD Chapter 17. Monoclonal Antibodies Including Immunoconjugates
Antibody-Drug Conjugates
Immunoconjugates
and Cytokine-Directed Agents by Alison Duffy
PharmD
BCOP and Ciera Bernhardi
PharmD
BCOP Chapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors
Vaccines
Bispecifics
and Engineered T Cells by Mark Yarchoan
MD and Elizabeth Jaffee
MD Index
MD
PhD and Ashkan Emadi
MD
PhD Chapter 2. Pharmacogenomics by Molly Graveno
PharmD
BCOP Chapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy
MD
Richard F. Little
MD
and Joshua F. Zeidner
MD Chapter 4. Drug Development and Regulatory Considerations by Vicky Hsu
PhD
Matthew D. Thompson
PhD
MPH
Donna Przepiorka
MD
PhD
and Olanrewaju O. Okusanya
Pharm.D.
MS PART 2. CLASSICAL CYTOTOXIC AGENTS Chapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi
MD
PhD and Edward A. Sausville
MD
PhD Chapter 6. Pyrimidine- and Purine-based Antimetabolites
Hydroxyurea
Asparaginases by Ashkan Emadi
MD
PhD and Judith E. Karp
MD Chapter 7. Antifolate Antimetabolites by Justin Lawson
PharmD
BCOP Chapter 8. Antimitotics by Edward A. Sausville
MD
PhD and Ashkan Emadi
MD
PhD PART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYS Chapter 9. Drugs Targeting DNA Repair
Cell Cycle and Apoptosis by Mira A. Kohorst
MD and Scott H. Kaufmann
MD
PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca
MD and Lukasz P. Gondek
MD
PhD Chapter 11. Differentiating Agents and Microenvironment by Yuya Nagai
MD
PhD and Gabriel Ghiaur
MD
PhD PART 4. ORGAN-TARGETED APPROACHES Chapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu
MD and Ashkan Emadi
MD
PhD Chapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton
PhD and Katherine H. R. Tkaczuk
MD Chapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar
PhD
and Arif Hussain
MD Chapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples
PharmD
BCOP and Sagar Lonial
MD PART 5. IMMUNE-TARGETED STRATEGIES Chapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic
MD Chapter 17. Monoclonal Antibodies Including Immunoconjugates
Antibody-Drug Conjugates
Immunoconjugates
and Cytokine-Directed Agents by Alison Duffy
PharmD
BCOP and Ciera Bernhardi
PharmD
BCOP Chapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors
Vaccines
Bispecifics
and Engineered T Cells by Mark Yarchoan
MD and Elizabeth Jaffee
MD Index
List of Contributors Preface PART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENT Chapter 1. Drug Development in Oncology 101 by Edward A. Sausville
MD
PhD and Ashkan Emadi
MD
PhD Chapter 2. Pharmacogenomics by Molly Graveno
PharmD
BCOP Chapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy
MD
Richard F. Little
MD
and Joshua F. Zeidner
MD Chapter 4. Drug Development and Regulatory Considerations by Vicky Hsu
PhD
Matthew D. Thompson
PhD
MPH
Donna Przepiorka
MD
PhD
and Olanrewaju O. Okusanya
Pharm.D.
MS PART 2. CLASSICAL CYTOTOXIC AGENTS Chapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi
MD
PhD and Edward A. Sausville
MD
PhD Chapter 6. Pyrimidine- and Purine-based Antimetabolites
Hydroxyurea
Asparaginases by Ashkan Emadi
MD
PhD and Judith E. Karp
MD Chapter 7. Antifolate Antimetabolites by Justin Lawson
PharmD
BCOP Chapter 8. Antimitotics by Edward A. Sausville
MD
PhD and Ashkan Emadi
MD
PhD PART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYS Chapter 9. Drugs Targeting DNA Repair
Cell Cycle and Apoptosis by Mira A. Kohorst
MD and Scott H. Kaufmann
MD
PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca
MD and Lukasz P. Gondek
MD
PhD Chapter 11. Differentiating Agents and Microenvironment by Yuya Nagai
MD
PhD and Gabriel Ghiaur
MD
PhD PART 4. ORGAN-TARGETED APPROACHES Chapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu
MD and Ashkan Emadi
MD
PhD Chapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton
PhD and Katherine H. R. Tkaczuk
MD Chapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar
PhD
and Arif Hussain
MD Chapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples
PharmD
BCOP and Sagar Lonial
MD PART 5. IMMUNE-TARGETED STRATEGIES Chapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic
MD Chapter 17. Monoclonal Antibodies Including Immunoconjugates
Antibody-Drug Conjugates
Immunoconjugates
and Cytokine-Directed Agents by Alison Duffy
PharmD
BCOP and Ciera Bernhardi
PharmD
BCOP Chapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors
Vaccines
Bispecifics
and Engineered T Cells by Mark Yarchoan
MD and Elizabeth Jaffee
MD Index
MD
PhD and Ashkan Emadi
MD
PhD Chapter 2. Pharmacogenomics by Molly Graveno
PharmD
BCOP Chapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy
MD
Richard F. Little
MD
and Joshua F. Zeidner
MD Chapter 4. Drug Development and Regulatory Considerations by Vicky Hsu
PhD
Matthew D. Thompson
PhD
MPH
Donna Przepiorka
MD
PhD
and Olanrewaju O. Okusanya
Pharm.D.
MS PART 2. CLASSICAL CYTOTOXIC AGENTS Chapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi
MD
PhD and Edward A. Sausville
MD
PhD Chapter 6. Pyrimidine- and Purine-based Antimetabolites
Hydroxyurea
Asparaginases by Ashkan Emadi
MD
PhD and Judith E. Karp
MD Chapter 7. Antifolate Antimetabolites by Justin Lawson
PharmD
BCOP Chapter 8. Antimitotics by Edward A. Sausville
MD
PhD and Ashkan Emadi
MD
PhD PART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYS Chapter 9. Drugs Targeting DNA Repair
Cell Cycle and Apoptosis by Mira A. Kohorst
MD and Scott H. Kaufmann
MD
PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca
MD and Lukasz P. Gondek
MD
PhD Chapter 11. Differentiating Agents and Microenvironment by Yuya Nagai
MD
PhD and Gabriel Ghiaur
MD
PhD PART 4. ORGAN-TARGETED APPROACHES Chapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu
MD and Ashkan Emadi
MD
PhD Chapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton
PhD and Katherine H. R. Tkaczuk
MD Chapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar
PhD
and Arif Hussain
MD Chapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples
PharmD
BCOP and Sagar Lonial
MD PART 5. IMMUNE-TARGETED STRATEGIES Chapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic
MD Chapter 17. Monoclonal Antibodies Including Immunoconjugates
Antibody-Drug Conjugates
Immunoconjugates
and Cytokine-Directed Agents by Alison Duffy
PharmD
BCOP and Ciera Bernhardi
PharmD
BCOP Chapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors
Vaccines
Bispecifics
and Engineered T Cells by Mark Yarchoan
MD and Elizabeth Jaffee
MD Index